Atricure Inc (ATRC) 15.29 $ATRC AtriCure Announces the

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Atricure Inc (ATRC) 15.29 $ATRC

AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
BusinessWire - Tue Jun 21, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI. This company-sponsored trial will evaluate intraoperative cryoanalgesia therapy using cryoablation in conjunction with standard of care (SOC) pain management compared to SOC alone.
ATRC: 15.29 (+0.10)

AtriCure to Present at the UBS Global Healthcare Conference
BusinessWire - Mon May 02, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
ATRC: 15.29 (+0.10)

AtriCure Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:05PM CDT
--U.S. sales of $28.3 million - up 23.3%
ATRC: 15.29 (+0.10)

AtriCure Announces $25 Million Term Loan with Silicon Valley Bank
BusinessWire - Thu Apr 28, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 million revolving line of credit.
ATRC: 15.29 (+0.10)

AtriCure Receives FDA Clearance for New AtriClip(R) Device
BusinessWire - Tue Apr 26, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system has increased functionality which enhances the capability to occlude the LAA during minimally-invasive surgical (MIS) procedures.
ATRC: 15.29 (+0.10)

New Strong Buy Stocks for April 19th
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 8:33AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BMA: 73.51 (-1.62), BV: 4.16 (+0.01), ANCX: 22.03 (-0.20), MTGE: 16.43 (+0.07), ATRC: 15.29 (+0.10)

What Falling Estimates & Price Mean for INSYS Therapeutics (INSY)
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 4:59PM CDT
INSYS Therapeutics has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
INSY: 15.94 (+0.29), ATRC: 15.29 (+0.10)

AtriCure Announces 510(k) Clearance for the cryoFORM(TM) Cryoablation Probe
BusinessWire - Tue Apr 12, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received 510(k) clearance for the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety of surgical ablation procedures. The probe was previously launched in October 2015 in the European market under a CE mark.
ATRC: 15.29 (+0.10)

AtriCure to Announce First Quarter 2016 Financial Results
BusinessWire - Tue Apr 05, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the first quarter of 2016 on Thursday, April 28, 2016.
ATRC: 15.29 (+0.10)

New Strong Buy Stocks for March 29th
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:06AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BPMC: 22.34 (+0.23), BXE: 0.83 (-0.03), BKCC: 8.31 (-0.05), AKAO: 3.71 (-0.22), ATRC: 15.29 (+0.10)

New Strong Buy Stocks for March 21st
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 9:04AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BV: 4.16 (+0.01), ESIO: 6.94 (+0.17), CIDM: 1.68 (+0.07), ATRC: 15.29 (+0.10), CGNT: 1.06 (+0.05)

Phibro Animal Health (PAHC) in Focus: Stock Jumps 5.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 7:35AM CDT
Phibro Animal Health Corporation (PAHC) was a big mover last session, as the company saw its shares rise over 5% on the day.
PAHC: 20.72 (+0.09), ATRC: 15.29 (+0.10)

Shares of ATRC Down 16.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 07, 9:32AM CST
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on January 8th, 2016 at $20.08. In approximately 2 months, AtriCure has returned 16.36% as of today's recent price of $16.79.
ATRC: 15.29 (+0.10)

AtriCure Down 19.0% Since SmarTrend Downtrend Call (ATRC)
Comtex SmarTrend(R) - Tue Feb 09, 10:17AM CST
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on January 8th, 2016 at $20.08. In approximately 1 month, AtriCure has returned 19.00% as of today's recent price of $16.26.
ATRC: 15.29 (+0.10)

AtriCure to Announce Fourth Quarter and Full Year 2015 Financial Results
BusinessWire - Mon Feb 01, 3:00PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the fourth quarter and full year 2015 on Tuesday, February 23, 2016.
ATRC: 15.29 (+0.10)

Downtrend Call Working As AtriCure Stock Falls 16.6% (ATRC)
Comtex SmarTrend(R) - Fri Jan 29, 10:48AM CST
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on January 8th, 2016 at $20.08. In approximately 3 weeks, AtriCure has returned 16.56% as of today's recent price of $16.75.
ATRC: 15.29 (+0.10)

AtriCure to Present at the Leerink Global Healthcare Conference
BusinessWire - Thu Jan 21, 7:00AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 11, 2016. Management is scheduled to present at 8:05 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
ATRC: 15.29 (+0.10)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 91

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 26

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 43

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 101

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 44

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 20

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 13

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 114

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading

Top 5 Most Recently Viewed Articles

CSX Corporation Teams Up for Q1 Earnings Conference Call

Updated Category News Views 131

CSX Corporation's Upcoming First Quarter Earnings Release CSX Corporation (NASDAQ: CSX) is excited to announce its first-quarter earnings release slated for a date following the market close. This pivotal moment will take place on a Wednesday, with management inviting participants to join their insightful conference call. Details of the Earnings Call A live webcast and...

Continue Reading
Innovative ReWalk 7 Exoskeleton Now Available for All Users

Updated Category News Views 345

The Launch of ReWalk 7 Personal Exoskeleton Lifeward Ltd., known for its groundbreaking innovations in medical technology, has recently unveiled its seventh generation of personal exoskeletons, the ReWalk 7. This next-generation device is now available throughout the United States, primarily aiming to benefit individuals with spinal cord injuries (SCI). This remarkable...

Continue Reading
Eve's Certification Progress Marks Aviation Milestone

Updated Category News Views 51

Certification: A New Lease on Air Mobility Folks, the air mobility future is taking one giant leap forward, and Eve Air Mobility is right at the helm. With Brazil’s aviation authority spearheading a consultation for updated airworthiness criteria and Eve stepping up for European certification, these advancements aren't just footnotes—they're headlines. NYSE:EVEX has...

Continue Reading
Exciting Launch of Lofthill Residences: A Premier Investment Hub

Updated Category News Views 164

Lofthill Residences: A Fresh Investment Opportunity in Kuala Lumpur The real estate market in Kuala Lumpur has taken an exciting turn with the introduction of Lofthill Residences, a groundbreaking initiative by TRE Towers and the Armani Group. Conveniently located near the vibrant KLCC and just a short walk from the Raja Uda MRT station, this development stands out as a...

Continue Reading
Exclaimer Welcomes Rob Singer as CEO to Propel Growth

Updated Category News Views 385

Exclaimer Welcomes New Leadership for Future Growth Exclaimer, a leader in email signature management, has announced the appointment of Rob Singer as its new CEO. This comes at a key moment for the company, which has recently doubled its annual revenue and is set to expand its presence with new offices opening soon. Experience and Vision Matter Rob Singer comes to...

Continue Reading